Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Research & Development (2016 - 2025)

Historic Research & Development for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $13.6 million.

  • Avalo Therapeutics' Research & Development rose 4280.77% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 14832.25%. This contributed to the annual value of $24.4 million for FY2024, which is 7728.53% up from last year.
  • As of Q3 2025, Avalo Therapeutics' Research & Development stood at $13.6 million, which was up 4280.77% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Research & Development registered a high of $25.2 million during Q1 2021, and its lowest value of $1.2 million during Q3 2023.
  • For the 5-year period, Avalo Therapeutics' Research & Development averaged around $8.7 million, with its median value being $8.5 million (2022).
  • Per our database at Business Quant, Avalo Therapeutics' Research & Development crashed by 8226.36% in 2023 and then soared by 66365.09% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Research & Development stood at $11.5 million in 2021, then plummeted by 46.38% to $6.2 million in 2022, then tumbled by 69.75% to $1.9 million in 2023, then skyrocketed by 338.3% to $8.2 million in 2024, then surged by 66.45% to $13.6 million in 2025.
  • Its Research & Development was $13.6 million in Q3 2025, compared to $14.1 million in Q2 2025 and $9.1 million in Q1 2025.